Drug Profile
Surinabant
Alternative Names: SR147778Latest Information Update: 04 Nov 2008
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Amides; Drug withdrawal therapies; Obesity therapies; Piperidines; Pyrazoles; Smoking cessation therapies
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alcoholism; Obesity; Psychotic disorders; Smoking withdrawal
Most Recent Events
- 24 Jun 2018 Biomarkers information updated
- 31 Oct 2008 Discontinued - Phase-II for Smoking withdrawal in European Union (PO)
- 07 Mar 2005 Phase-II clinical trials in Obesity in France (unspecified route)